 |
Monday, April 3rd |
Time |
Description |
| |
|
7:30 AM |
Registration and Exhibit Hall opens. Continental breakfast
available. |
| |
|
8:45 AM |
Welcome Remarks
- Al Kolb, SBS President (Key Tech Solutions) |
| |
|
|
|
| |
|
8:50 AM |
Session I Introduction: Life sciences in the chemical
genomic era
- Doug Burdette, SBS Regional Meeting Committee Co-chair |
| |
|
9:00-9:45 |
Chemical Genetic Studies of the Ubiquitin-Proteasome System
- Randy King (Harvard) |
| |
|
9:45-10:15 |
NIH Roadmap overview and the role of chemical genomics
- Chris Austin (NIH) |
| |
|
10:15-10:45 |
Break - Exhibit Hall open |
| |
|
10:45-11:15 |
MLSCN screening experiences
- Jim Inglese SBS Regional Meeting Committee
Chair |
| |
|
11:15-11:45 |
Academic centers, the MLSCN, and bridging the academic industry gap
- Scott Diamond, University of Pennsylvania |
| |
|
11:45-12:30 |
IP - Open (MLSCN) approach vs. Protective (traditional
corporate) approach
- Chris Austin (NIH), Marcy Glicksman (Harvard) |
| |
|
12:30-2:00 |
Lunch - Exhibit Hall open |
| |
|
2:00-3:00 |
Education workshops (choose one of these concurrent
workshops) |
| |
|
A) |
Modeling QSAR data and evaluation of HTS variability
- Viswanath Devanarayan (Merck Research Laboratories), Andy Liaw (Merck Research Laboratories) |
| |
|
B) |
Designing and curating compound collections (filtering
compound aggregation and data management)
- Jack Friday (Pfizer) and Tim Lease (Drug Discovery Partners International) |
| |
|
C) |
NIH Roadmap Funding Opportunities for Assay Development and HTS (incl. assembling X01-RFA applications for NIH
Center for Chemical Genomics)
- Caroline Shamu (Harvard Medical School),Mark
Scheideler (NIH) and John Schwab |
| |
|
|
|
| |
|
3:00 PM |
Richard Eglen
Session II Introduction: Bridging industry and academics
from the industry viewpoint |
| |
|
3:10-3:40 |
Success Story from Pfizer's Drug Pfinder Initiative
- Patricia Soulard (Pfizer) |
| |
|
3:40-4:10 |
HTS from the Industrial Perspective
- Angela Cacace (Bristol-Myers Squibb) |
| |
|
4:10-4:30 |
Break - Exhibit Hall open |
| |
|
4:30-5:15 |
Vendor tutorials (choose one of these concurrent tutorials) |
| |
|
|
Invitrogen |
| |
|
|
Cisbio international |
| |
|
|
|
| |
|
5:15-6:30 |
Networking Reception in Exhibit Hall |
| |
|
|
|
| |
|
|
|
| |
Tuesday, April 4th |
7:45 AM |
Registration and Exhibit Hall opens. Continental breakfast
available. |
| |
|
|
|
| |
|
8:30 AM |
Session III: Target biology for rare disorders
- Jim Inglese, Regional Meeting Committee Chair (NIH)
|
| |
|
8:45-9:15 |
Alternative splicing as a drug target: The example of progeria
- Tom Misteli (NIH) |
| |
|
9:15-9:45 |
Gaucher Disease
- Ellen Sidransky (NIH) |
| |
|
9:45-10:15 |
Break - Exhibit Hall open |
| |
|
10:45-11:15 |
Non Profit Rare Disorders
- Jill Jarecki (Families of Spinal Muscular Atrophy) |
| |
|
10:15-10:45 |
Anthrax: Biodefense Target and model system for other
infectious diseases
- Thomas Bugge (NIH) |
| |
|
11:15-12:00 |
Vendor tutorials |
| |
|
|
BD Biosciences |
| |
|
|
Corning, Inc. |
| |
|
|
Guava Technologies |
| |
|
|
|
| |
|
12:00-1:30 |
Lunch - Exhibit Hall open |
| |
|
|
|
| |
|
1:30-1:45 |
Session IV Introduction: Translation of academic drug
discovery to the clinic
- Al Kolb, SBS President (Key Tech Solutions) |
| |
|
1:45-2:15 |
You've Got Hits Now What?
- Caroline Shamu (Harvard Medical School) |
| |
|
2:15-3:00 |
Translational medicine: the hit to clinic process from
an academic perspective
- Soumya Ray (Harvard) |
| |
|
3:00-3:15 |
Closing remarks
Funding summary and the role of the SBS in Academia
- Richard Eglen, SBS Board Member (DiscoveRx) |
| |
|
|
|
| |
|
|
|